| 1 |
Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock [J]. Chest, 2009, 136(5): 1237-1248.
|
| 2 |
Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill [J]. Intensive Care Med, 2013, 39(12): 2070-2082.
|
| 3 |
Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions [J]. Lancet Infect Dis, 2014, 14(6): 498-509.
|
| 4 |
柳晓泉. 经典的房室模型理论[A]//王广基. 药物代谢动力学 [M]. 北京: 化学工业出版社, 2005: 68-39.
|
| 5 |
Smith DA, Beaumont K, Maurer TS, et al. Volume of distribution in drug design [J]. J Med Chem, 2015, 58(15): 5691-5698.
|
| 6 |
Marta U, Jordi R. The relevance of drug volume of distribution in antibiotic dosing [J]. Curr Pharm Biotechnol, 2011, 12(12): 1996-2001.
|
| 7 |
Marta U, Jason AR, Jordi R, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients [J]. Clin Pharmacokinet, 2011, 50(2): 99-110.
|
| 8 |
Janice BS. The influence of sex on pharmacokinetics [J]. Clin Pharmacokinet, 2003, 42(11): 985-996.
|
| 9 |
Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults [J]. Lancet, 2010, 375 (9710): 248-251.
|
| 10 |
Bauer LA, Blouin RA, Griffen WO Jr, et al. Amikacin pharmackinetics in morbidly obese patients [J]. Am J Hosp Pharm, 1980, 37(4): 519-522.
|
| 11 |
Rughoo L, Bourguignon L, Maire P, et al. Study of relationship between volume of distribution and body weight application to amikacin [J]. Eur J Drug Metab Pharmacokinet, 2014, 39(2): 87-91.
|
| 12 |
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient [J]. Crit Care Med, 2009, 37(3): 840-851.
|
| 13 |
McKindley DS, Boucher BA, Hess MM, et al. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia [J]. Pharmacotherapy, 1996, 16(5): 924-931.
|
| 14 |
Lipman J, Wallis SC, Rickard CM, et al. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing [J]. Intensive Care Med, 2001, 27(2): 363-370.
|
| 15 |
Triginer C, Izquierdo I, Fernández R, et al. Gentamicin volume of distribution in critically ill septic patients [J]. Intensive Care Med, 1990, 16(5): 303-306.
|
| 16 |
Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients [J]. Anaesth Intensive Care, 1993, 21(2): 172-173.
|
| 17 |
Imaura M, Yokoyama H, Kohata Y, et al. Initial dosing regimen of vancomycin to achieve early therapeutic plasma concentration in critically ill patients with MRSA infection based on APACHEⅡ score [J]. Eur J Drug Metab Pharmacokinet, 2016, 41(3): 211-218.
|
| 18 |
Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability [J]. Clin Pharmacokinet, 2005, 44(10): 1009-1034.
|
| 19 |
Gous AG, Dance MD, Lipman J, et al. Changes in vancomycin pharmacokinetics in critically ill infants [J]. Anaesth Intensive Care, 1995, 23 (6): 678-682.
|
| 20 |
Gustavo L, Gilberto CH. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis [J]. Crit Care Med, 1997, 25(5): 806-811.
|
| 21 |
黄英姿，邱海波. 药代动力学导向的重症感染患者抗生素个体化与精准化治疗 [J]. 中华内科杂志, 2016, 55(55): 425-427.
|